{"id":10238,"date":"2026-06-23T14:15:00","date_gmt":"2026-06-23T18:15:00","guid":{"rendered":"https:\/\/progresso.com.br\/?p=10238"},"modified":"2026-06-23T13:36:47","modified_gmt":"2026-06-23T17:36:47","slug":"anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2","status":"publish","type":"post","link":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/","title":{"rendered":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong><em>Indica\u00e7\u00e3o \u00e9 para adultos com tumor que n\u00e3o pode ser removido<\/em><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Paula Laboissi\u00e8re \u2013Ag\u00eancia Brasil<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa)&nbsp;<a href=\"https:\/\/www.in.gov.br\/web\/dou\/-\/resolucao-re-n-2.465-de-18-de-junho-de-2026-713601467\" target=\"_blank\" rel=\"noreferrer noopener\">publicou<\/a>&nbsp;esta semana o registro do&nbsp;medicamento Inluriyo\u00ae (tosilato de inlunestranto), indicado para adultos com c\u00e2ncer de mama localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras partes do corpo e que foi previamente tratado com terapia end\u00f3crina.<\/strong><img decoding=\"async\" src=\"https:\/\/agenciabrasil.ebc.com.br\/ebc.png?id=1694452&amp;o=node\"><img decoding=\"async\" src=\"https:\/\/agenciabrasil.ebc.com.br\/ebc.gif?id=1694452&amp;o=node\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Em nota, a ag\u00eancia detalhou que esse tipo de tumor apresenta as seguintes caracter\u00edsticas: \u00e9 positivo para receptor de estrog\u00eanio (ER+), negativo para receptor 2 do fator de crescimento epid\u00e9rmico humano (HER2-) e tem muta\u00e7\u00e3o no receptor de estrog\u00eanio 1 (ESR1m).<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">\u201cO medicamento, desenvolvido pela Eli Lilly do Brasil Ltda., \u00e9 oral e indicado como monoterapia.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>De acordo com a Anvisa, o c\u00e2ncer de mama figura como a neoplasia maligna de maior incid\u00eancia entre mulheres.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">No Brasil, dados do Instituto Nacional do C\u00e2ncer (Inca) indicam que, no per\u00edodo entre 2023 e 2025, foram registrados 73.610 casos da doen\u00e7a. O n\u00famero representa 30,1% do total de c\u00e2nceres em mulheres.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Indica\u00e7\u00e3o \u00e9 para adultos com tumor que n\u00e3o pode ser removido Paula Laboissi\u00e8re \u2013Ag\u00eancia Brasil A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa)&nbsp;publicou&nbsp;esta semana o registro do&nbsp;medicamento Inluriyo\u00ae (tosilato de inlunestranto), indicado para adultos com c\u00e2ncer de mama localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras partes do [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":10239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,2],"tags":[],"class_list":["post-10238","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cotidiano","category-destaque"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO\" \/>\n<meta property=\"og:description\" content=\"Indica\u00e7\u00e3o \u00e9 para adultos com tumor que n\u00e3o pode ser removido Paula Laboissi\u00e8re \u2013Ag\u00eancia Brasil A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa)&nbsp;publicou&nbsp;esta semana o registro do&nbsp;medicamento Inluriyo\u00ae (tosilato de inlunestranto), indicado para adultos com c\u00e2ncer de mama localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras partes do [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\" \/>\n<meta property=\"og:site_name\" content=\"O PROGRESSO\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T18:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1170\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Rose\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Rose\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\"},\"author\":{\"name\":\"Rose\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b\"},\"headline\":\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama\",\"datePublished\":\"2026-06-23T18:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\"},\"wordCount\":205,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/progresso.com.br\/#organization\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp\",\"articleSection\":[\"Cotidiano\",\"Em destaque\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\",\"url\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\",\"name\":\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO\",\"isPartOf\":{\"@id\":\"https:\/\/progresso.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp\",\"datePublished\":\"2026-06-23T18:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage\",\"url\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp\",\"contentUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp\",\"width\":1170,\"height\":700,\"caption\":\"(Valter Campanato\/Ag\u00eancia Brasil)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/progresso.com.br\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/progresso.com.br\/#website\",\"url\":\"https:\/\/progresso.com.br\/\",\"name\":\"O PROGRESSO\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/progresso.com.br\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/progresso.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/progresso.com.br\/#organization\",\"name\":\"O PROGRESSO\",\"url\":\"https:\/\/progresso.com.br\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg\",\"contentUrl\":\"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg\",\"width\":1960,\"height\":1080,\"caption\":\"O PROGRESSO\"},\"image\":{\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/\",\"https:\/\/www.instagram.com\/oprogresso_digital\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b\",\"name\":\"Rose\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/progresso.com.br\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g\",\"caption\":\"Rose\"},\"url\":\"https:\/\/progresso.com.br\/index.php\/author\/rose\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/","og_locale":"pt_BR","og_type":"article","og_title":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO","og_description":"Indica\u00e7\u00e3o \u00e9 para adultos com tumor que n\u00e3o pode ser removido Paula Laboissi\u00e8re \u2013Ag\u00eancia Brasil A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa)&nbsp;publicou&nbsp;esta semana o registro do&nbsp;medicamento Inluriyo\u00ae (tosilato de inlunestranto), indicado para adultos com c\u00e2ncer de mama localmente avan\u00e7ado, que n\u00e3o pode ser removido por cirurgia ou que j\u00e1 se espalhou para outras partes do [&hellip;]","og_url":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/","og_site_name":"O PROGRESSO","article_publisher":"https:\/\/www.facebook.com\/share\/1CeoksKBj6\/","article_published_time":"2026-06-23T18:15:00+00:00","og_image":[{"width":1170,"height":700,"url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp","type":"image\/webp"}],"author":"Rose","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Rose","Est. tempo de leitura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#article","isPartOf":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/"},"author":{"name":"Rose","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b"},"headline":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama","datePublished":"2026-06-23T18:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/"},"wordCount":205,"commentCount":0,"publisher":{"@id":"https:\/\/progresso.com.br\/#organization"},"image":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage"},"thumbnailUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp","articleSection":["Cotidiano","Em destaque"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/","url":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/","name":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama - O PROGRESSO","isPartOf":{"@id":"https:\/\/progresso.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage"},"image":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage"},"thumbnailUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp","datePublished":"2026-06-23T18:15:00+00:00","breadcrumb":{"@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#primaryimage","url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp","contentUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/06\/0d7a5833-1.webp","width":1170,"height":700,"caption":"(Valter Campanato\/Ag\u00eancia Brasil)"},{"@type":"BreadcrumbList","@id":"https:\/\/progresso.com.br\/index.php\/2026\/06\/23\/anvisa-aprova-novo-medicamento-oral-para-cancer-de-mama-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/progresso.com.br\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova novo medicamento oral para c\u00e2ncer de mama"}]},{"@type":"WebSite","@id":"https:\/\/progresso.com.br\/#website","url":"https:\/\/progresso.com.br\/","name":"O PROGRESSO","description":"","publisher":{"@id":"https:\/\/progresso.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/progresso.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/progresso.com.br\/#organization","name":"O PROGRESSO","url":"https:\/\/progresso.com.br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg","contentUrl":"https:\/\/progresso.com.br\/wp-content\/uploads\/2026\/03\/logo_proog.jpg","width":1960,"height":1080,"caption":"O PROGRESSO"},"image":{"@id":"https:\/\/progresso.com.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/share\/1CeoksKBj6\/","https:\/\/www.instagram.com\/oprogresso_digital"]},{"@type":"Person","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/5dd27138d4463fbbaace62120bfc002b","name":"Rose","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/progresso.com.br\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1b6890e759cdd3a88d9f751cb423720b9861c5239167cd3586355638b6556599?s=96&d=mm&r=g","caption":"Rose"},"url":"https:\/\/progresso.com.br\/index.php\/author\/rose\/"}]}},"_links":{"self":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/10238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/comments?post=10238"}],"version-history":[{"count":1,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/10238\/revisions"}],"predecessor-version":[{"id":10240,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/posts\/10238\/revisions\/10240"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/media\/10239"}],"wp:attachment":[{"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/media?parent=10238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/categories?post=10238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/progresso.com.br\/index.php\/wp-json\/wp\/v2\/tags?post=10238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}